Showing results (181-190 of 261) with videos related to
Sort By:
Pageof 27
American Journal of Clinical Dermatology|September 24, 2025
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and AdultsRichard G Langley, Guy Gherardi, Anna Coleman, et al.The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.JID Innovations : Skin Science From Molecules to Population Health|August 8, 2024
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 SubstudyAndrew Blauvelt, Richard G Langley, Patrick J Branigan, et al.Journal of the American Academy of Dermatology|March 1, 2014
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyMark G Lebwohl, Hervé Bachelez, Jonathan Barker, et al.JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2015
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyP C M van de Kerkhof, K Reich, A Kavanaugh, et al.The British Journal of Dermatology|June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studiesA Blauvelt, C Paul, P van de Kerkhof, et al.The New England Journal of Medicine|January 18, 2008
Etanercept treatment for children and adolescents with plaque psoriasisAmy S Paller, Elaine C Siegfried, Richard G Langley, et al.Pageof 27